Planchard D, Smit EF, Solomon BJ, Veronesi G, Reck M; ESMO Guidelines Committee. Non-oncogene addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up†. Ann Oncol. 2023 Jan 3:S0923-7534(22)04785-8. ...
Planchard D, Smit EF, Solomon BJ, Veronesi G, Reck M; ESMO Guidelines Committee. Non-oncogene addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up†. Ann Oncol. 2023 Jan 3:S0923-7534(22)04785-8. ...
[9] Janne P, Goto Y, Kubo T, et al. Trastuzumab Deruxtecan in Patients with HER2-Mutant Metastatic Non-Small Cell Lung Cancer: Primary Results of DESTINY-Lung02. 2023 WCLC. MA13.10. [10] NCCN Clinical Practice Gu...
2.Zhang S, Wang W, Xu C, et al. Chinese expert consensus on the diagnosis and treatment of HER2-altered non-small cell lung cancer[J]. Thorac Cancer. 2023 Jan;14(1):91-104. 3.NCCN Clinical Practice Guidelines in Oncology:Non-Small Cell Lung Cancer(Version 3.2023). 4.CSCO 非小细胞...
3.NCCN Clinical Practice Guidelines in Oncology:Non-Small Cell Lung Cancer(Version 3.2023). 4.CSCO 非小细胞肺癌诊疗指南(2023版). 5. Lin JJ, Gainor JF. Time to tackle the blood-brain barrier in HER2-mutant lung can...
[10] NCCN Guidelines Version 5.2022 Lung Cancer. [11] Rebuzzi SE, Alfieri R, La Monica S, et al. Combination of EGFR-TKIs and chemotherapy in advanced EGFR mutated NSCLC: Review of the literature and future perspectives. Crit Rev Oncol Hematol. 2020 Feb;146:102820. ...
[12] Shirong Zhang, Wenxian Wang, Chunwei Xu, et al. Chinese expert consensus on the diagnosis and treatment of HER2-altered non–small cell lung cancer. Thorac Cancer. 2023;14:91–104. [13] NCCN Clinical Practice Guidelines in Oncology:Non-Small Cell Lung Cancer(Version 5.2024) ...
ESMO advanced lung cancer GuidelinesS. Peters
4. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Non‑Small Cell Lung Cancer. V.3.2023. https:/ /www.nccn.org/professionals/physician_gls/pdf/nscl. pdf. Accessed July 24, 2023.
[3]NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Non-Small Cell Lung Cancer. Version 7.2024. [5]Fan Y, et al. High-dose almonertinib in treatment-native EGFR-mutated NSCLC with CNS metastases: Efficacy and biomarker analysis. 2024 ASCO, abstract 2007. ...